Literature DB >> 20411047

Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity.

Adam J Adler1.   

Abstract

Due to the random generation of T cell antigen receptors, a large fraction of developing T cells have the potential to recognize self-determinants. To prevent this self-reactive T cell repertoire from mediating autoimmunity, the immune system utilizes several mechanisms to induce tolerance to self. The majority of self-reactive T cells undergo negative selection (i.e., apoptosis) during development if their antigen receptors have high affinity for MHC-self-peptide complexes present in the thymus. Nonetheless, some T cells recognize self-epitopes that are not present in the thymus, and will thus reach maturation and migrate to peripheral lymphoid organs were they can be subject to a number of peripheral tolerance mechanisms such as deletion, inactivation (i.e., anergy) or suppression. While peripheral tolerization of naive (i.e., antigen-inexperienced) T cells has been studied extensively, there are potential situations in which self-reactive T cells might first encounter immunogenic forms of antigen (deriving from pathogens or vaccines) and thus be programmed to develop effector and memory functions. This article will review recent studies that have explored the potential of effector and memory T cells to undergo peripheral tolerization, as well as potential implications of these findings for autoimmunity and tumor-immunity.

Entities:  

Year:  2005        PMID: 20411047      PMCID: PMC2857346          DOI: 10.2174/1573395052952879

Source DB:  PubMed          Journal:  Curr Immunol Rev        ISSN: 1573-3955


  94 in total

1.  CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement.

Authors:  Amy D Higgins; Marianne A Mihalyo; Patrick W McGary; Adam J Adler
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Memory CD8(+) T cells undergo peripheral tolerance.

Authors:  Huub T C Kreuwel; Sandra Aung; Cheryl Silao; Linda A Sherman
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

Review 3.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

4.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.

Authors:  S Brocke; K Gijbels; M Allegretta; I Ferber; C Piercy; T Blankenstein; R Martin; U Utz; N Karin; D Mitchell; T Veromaa; A Waisman; A Gaur; P Conlon; N Ling; P J Fairchild; D C Wraith; A O'Garra; C G Fathman; L Steinman
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

5.  Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

Authors:  Tanina A Cordaro; Karin E de Visser; Felicia H Tirion; Ton N M Schumacher; Ada M Kruisbeek
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

6.  A functional and structural basis for TCR cross-reactivity in multiple sclerosis.

Authors:  Heather L E Lang; Helle Jacobsen; Shinji Ikemizu; Christina Andersson; Karl Harlos; Lars Madsen; Peter Hjorth; Leif Sondergaard; Arne Svejgaard; Kai Wucherpfennig; David I Stuart; John I Bell; E Yvonne Jones; Lars Fugger
Journal:  Nat Immunol       Date:  2002-09-03       Impact factor: 25.606

7.  TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.

Authors:  Christian H Poehlein; Hong-Ming Hu; Jane Yamada; Ilka Assmann; W Gregory Alvord; Walter J Urba; Bernard A Fox
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

8.  Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

Authors:  P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

Review 9.  The role of CD95 in the regulation of peripheral T-cell apoptosis.

Authors:  Andreas Krueger; Stefanie C Fas; Sven Baumann; Peter H Krammer
Journal:  Immunol Rev       Date:  2003-06       Impact factor: 12.988

10.  CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.

Authors:  A J Adler; D W Marsh; G S Yochum; J L Guzzo; A Nigam; W G Nelson; D M Pardoll
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

View more
  4 in total

1.  T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression.

Authors:  Meixiao Long; Aaron M Slaiby; Adam T Hagymasi; Marianne A Mihalyo; Alexander C Lichtler; Steven L Reiner; Adam J Adler
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

Review 2.  Targeting and utilizing primary tumors as live vaccines: changing strategies.

Authors:  Xuanming Yang; Eric D Mortenson; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2011-11-21       Impact factor: 11.530

3.  Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen.

Authors:  Meixiao Long; Aaron M Slaiby; Shuang Wu; Adam T Hagymasi; Marianne A Mihalyo; Suman Bandyopadhyay; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

4.  Tolerogenic Immunomodulation by PEGylated Antigenic Peptides.

Authors:  Jennifer Pfeil; Mario Simonetti; Uta Lauer; Rudolf Volkmer; Bianca von Thülen; Pawel Durek; Ralf Krähmer; Frank Leenders; Alf Hamann; Ute Hoffmann
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.